These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21928084)

  • 1. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.
    Santos PC; Gagliardi AC; Miname MH; Chacra AP; Santos RD; Krieger JE; Pereira AC
    Eur J Clin Pharmacol; 2012 Mar; 68(3):273-9. PubMed ID: 21928084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
    Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
    Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
    Voora D; Shah SH; Spasojevic I; Ali S; Reed CR; Salisbury BA; Ginsburg GS
    J Am Coll Cardiol; 2009 Oct; 54(17):1609-16. PubMed ID: 19833260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
    Shabana MF; Mishriki AA; Issac MS; Bakhoum SW
    Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
    Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
    Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
    Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
    DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
    Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASSOCIATION OF SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE POLYMORPHISM WITH RESPONSE TO ATORVASTATIN AND ASSOCIATED MYOPATHY IN IRAQI DYSLIPIDEMIA PATIENTS.
    Dheyaa Aziz N; Abbood SH; Al-Mayali AH; Hadi NR
    Pol Merkur Lekarski; 2023; 51(5):496-503. PubMed ID: 38069850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.
    Rodrigues AC; Perin PM; Purim SG; Silbiger VN; Genvigir FD; Willrich MA; Arazi SS; Luchessi AD; Hirata MH; Bernik MM; Dorea EL; Santos C; Faludi AA; Bertolami MC; Salas A; Freire A; Lareu MV; Phillips C; Porras-Hurtado L; Fondevila M; Carracedo A; Hirata RD
    Int J Mol Sci; 2011; 12(9):5815-27. PubMed ID: 22016628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
    Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
    Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
    Hou Q; Li S; Li L; Li Y; Sun X; Tian H
    Medicine (Baltimore); 2015 Sep; 94(37):e1268. PubMed ID: 26376374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
    Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
    Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group.
    Santos PC; Soares RA; Nascimento RM; Machado-Coelho GL; Mill JG; Krieger JE; Pereira AC
    BMC Med Genet; 2011 Oct; 12():136. PubMed ID: 21992719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms.
    Linskey DW; English JD; Perry DA; Ochs-Balcom HM; Ma C; Isackson PJ; Vladutiu GD; Luzum JA
    Pharmacogenet Genomics; 2020 Dec; 30(9):208-211. PubMed ID: 32453264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
    de Keyser CE; Peters BJ; Becker ML; Visser LE; Uitterlinden AG; Klungel OH; Verstuyft C; Hofman A; Maitland-van der Zee AH; Stricker BH
    Pharmacogenet Genomics; 2014 Jan; 24(1):43-51. PubMed ID: 24263182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of protective haplotypes of the
    Favela-Mendoza AF; Rodríguez-Rodríguez BG; Rojas-Prado E; Chávez-Arreguin M; Aguilar-Velázquez JA; Martínez-Cortés G; Rangel-Villalobos H
    Per Med; 2021 Sep; 18(6):533-540. PubMed ID: 34674552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.
    Lee YJ; Lee MG; Lim LA; Jang SB; Chung JY
    Int J Clin Pharmacol Ther; 2010 Jan; 48(1):36-45. PubMed ID: 20040338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly.
    Akao H; Polisecki E; Kajinami K; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J; Packard C; Buckley BM; Schaefer EJ
    Atherosclerosis; 2012 Feb; 220(2):413-7. PubMed ID: 22189199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
    Danik JS; Chasman DI; MacFadyen JG; Nyberg F; Barratt BJ; Ridker PM
    Am Heart J; 2013 Jun; 165(6):1008-14. PubMed ID: 23708174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.
    Liu JE; Liu XY; Chen S; Zhang Y; Cai LY; Yang M; Lai WH; Ren B; Zhong SL
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1409-1416. PubMed ID: 28812116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.